

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قال الله تعالى

لِلَّهِ مُلْكُ السَّمَاوَاتِ وَالْأَرْضِ يَخْلُقُ مَا يَشَاءُ يَهْبِطُ لِمَنْ يَشَاءُ  
إِنَّا وَيَهْبِطُ لِمَنْ يَشَاءُ الذِّكْرَ (49) أَوْ يُرَوِّجُهُمْ ذُكْرَانًا  
وَإِنَّا وَيَجْعَلُ مَنْ يَشَاءُ عَقِيمًا إِنَّهُ عَلِيمٌ قَدِيرٌ (50)

صدق الله العظيم

سورة الشورى الآيات 50-49

## **Dedication**

I dedicate this research to

The people whose prayers help me and encourage me to the way success..

My mother .....

To my father .....

My brothers and sisters .....

My friends and my colleagues .....

The people, whom I love, respect and appreciate and everyone from whom I learned.....

## **Acknowledgment**

First of all I thank Allah for giving me the strength and patience to perform this work,.i would like to express the my deepest gratitude and respect to

**Dr.Mohieldin Abass Abdulla Elsayid** for his supervision, time, patience effort and invaluable advices, I would like to express my thank to the staff of dialysis center in Alribbat Hospital , my colleagues and friends for their support and help throughout study, to everybody who contributed to the success of this work.

## **Abstract**

This is a descriptive analytical study carried out in Khartoum state during the period of March 2012 to July 2012, to evaluate some haemostatic parameters among lives diseases patient .Fifty samples with diagnosed liver disease, were selected, and twenty five healthy individual were selected as control group The study population were liver disease patients that include two gall cholecystitis(4 %) ,six obstructive jaundice (12%) , eleven liver cirrhosis (22.0%) , eighteen HBV(36%) , eleven HCV (22%) , and two liver metastasis (4%). The gender distribution were females 33 (44.7 %), and males 42 (55.3%). The marital status among the study population was married46 (60.5%) and single 29 (39.5%). , 2.5 ml of venous blood withdrawn from each patient and control, placed in trisodium citrate container, then centrifuged to obtain platelets poor plasma (PPP)for measuring Prothrombin time (PT), activated thromboplastin time (APTT), thrombin time (TT) and fibrinogen level. .The compare mean of liver diseases each alone include that PT of cirrhosis ,jaundice ,HBV ,HCV, Gallcholecystitis, and liver metastasis are (20.0sec) The results were analyzed by SPSS version 11.5 and express as means; the results obtained showed that the means of PT (17.0sec), APTT (40.0sec), TT (19.0sec) and fibrinogen level (262.0mg/dl) respectively. The mean of PT, PTT, TT, and fibrinogen level of control group were (13.0sec), (31.0sec), (13.0sec), and (222.0mg/dl) respectively. The results showed highly significant differences between the mean values of patients in compare to controls in Prothrombin time PT (P.value <0.05), activated partial thromboplastin time APTT (P.value <0.05), thrombin time TT (P.value <0.05) and fibrinogen level (P.value <0.05). The result show

insignificant differences between age groups, sex ,marital status ,and disease types .

## ملخص البحث

هذه دراسة وصفية تحليلية أجريت في ولاية الخرطوم في الفترة من مارس 2012 الي يوليو 2012 لقياس بعض عوامل التجلط لدى مرضى الكبد السودانيين، تم اختيار خمسون من مرضى الكبد مشخصين مسبقاً كما تمأخذ خمسة وعشرون عينة من اصحاب كمجموعة ضابطة. تمأخذ 2.5 ملليلتر من الدم الوريدي من كل مريض وتم وضعه في حاوية تحتوي على مانع التجلط ثلاثي سترات الصوديوم واستخلص سائل البلازما فقير الصفائح الدموية لقياس، زمن البروثرومبين ، زمن الثرومبوبلاستين الجزيء المنشط ، زمن الثرومبين، ومستوى الفبرينوجين وتم تحليل النتائج بواسطة برنامج الحزم الاحصائية للعلوم الاجتماعية المحوسوب اصدارة 11.5 ، شملت الدراسة من امراض الكبد تليف الكبد(11) اليرقان الانسدادي(6) التهاب المرارة(2) التهاب الكبد الوبائي النوع ب(18) التهاب الكبد النوع س(11) واورام الكبد(2) من المرضي اظهرت الدراسة نسب امراض الكبد كالاتي تليف الكبد (22%) البرواثرومبين (12%) التهاب المرارة(4%) التهاب الكبد الوبائي النوع ب (36%) التهاب الكبد النوع س(22%) واورام الكبد (45%) شملت الدراسة من الذكور(30%) ومن الاناث 20 (44.7% المتزوجين 60.5%) وغير المتزوجين 29 (39.5%). تم حساب المتوسط وكانت النتائج كالاتي: زمن البرواثرومبين (17ثانيه) زمن الثرومبوبلاستين الجزيء المنشط (40ثانيه) الثرومبين(19ثانيه) ومستوى الفبرينوجين(262 ملجرام للدسلتر) للمرضي بينما كان المتوسط للبرواثرومبين (13ثانيه) الثرومبوبلاستين الجزيء المنشط (31ثانيه) الثرومبين (13ثانيه) ومستوى الفبرينوجين(222 ملجرام للدسلتر) في مجموعة الضبط. اظهرت النتائج وجود فروقات ذات دلالة احصائية معنويه بين المصابين بامراض الكبد في متosteats البرواثرومبين زمن الثرومبوبلاستين المنشط الجزيء زمن الثرومبين ومستوى الفبرينوجين (القيمه المعنويه اقل من 0.05). مقارنة بعينات المعادلين الطبيعيين ايضا لم تظهر الدراسة فروق ذات دلالة احصائيه بين الاجناس وايضا بين المتزوجين وغير المتزوجين

لكن اظهرت فروق ذات دلاله احصائيه بين الاعمار (القيمه المعنويه اقل من 05.)

## Contents

No.	Contents	Page
1.	الآية	I
2.	Dedication	II
3.	Acknowledgement	III
4.	Abstract (English)	IV
5.	Abstract (Arabic)	V
6.	List of contents	VI
7.	List of Tables	XII
8.	List of abbreviations	XIII
	Chapter One Introduction and Literature review	
1.1	General introduction	1
1.2	Literature Review	2
1.2.1	Hemostasis	2
1.2.1.1	Definition of haemostasis	2
1.2.1.2	Overview of haemostasis	3
1.2.1.3	Component of the haemostatic system	3

1.2.1.3.1	Blood vessel	5
1.2.3.2	Platelets	5
1.2.1.3.3	Coagulation system	7
1.2.1.3.3.1	Coagulation factors	10
1.2.1.3.3.2	Coagulation inhibitors	11
1.2.1.2.2.2	Haemostatic mechanism	12
1.2.1.4.1	Primary haemostasis	12
1.2.1.4.2	haemostasis	14
1.2.1.4.3	Fibrinolysis	16
1.2.1.5	Laboratory test of haemostasis:	17
1.2.1.5.1	Samples for coagulation testing	17
1.2.1.5.5	First line investigations:	18
1.2.1.5.3	Second line investigations:	20
1.2.1.6	Disorder of haemostasis:	21
1.2.1.6.1	Platelets disorders:	20
1.2.1.6.1.1. 1	Thrombocytopenia	20
1.2.1.6.1.1. 2	thrombocytosis	22
1.2.1.6.1.2	Qualitative platelets disorders	22

1.2.1.6.1.2.1	Hereditary qualitative platelets disorders:	22
1.2.1.6.1.2.2	Acquired qualitative platelets disorders	23
1.2.1.6.2.1	Inherited vascular disorders:	24
1.2.1.6.2.3	Lab diagnosis of vascular and platelets disorders	25
1.2.1.6.3	Coagulation disorders	26
1.2.1.6.3.2	Acquired coagulation disorders	32
1.3	The liver	34
1.3.1	Liver Diseases	35
1.3.2	Type of liver disease	36
1.3.2.1	Alcoholic Liver Disease:	37
1.3.2.2	Fatty Liver Diseases	37
1.3.3.3	Biliary Diseases:	37
1.3.3.4	Chronic Hepatitis	37
1.3.3.5	Liver Cirrhosis	37
1.4.0	Previous studies	41
1.5	Rationale:	42
1.5.1	General Objective	43

1.5.2	Specific Objective:	43
	Chapter Two Materials and Methods	
2.1	Study design	44
2.2	Study areas	44
2.3	Study population	44
2.4	Criteria	44
2.5	Exclusion Criteria	44
2.6	Sample size	44
2.7	Ethical consideration	45
2.8	Tool of data collection	45
2.9	Data analysis	46
2.10	Preparation of platelet poor plasma.	46
2.11	Methods	46
2.11.1	Thrombin time(TT)	47
2.11.2	Prothrombin time(PT)	48
2.11.3	Activated partial Thromboplastin.(APTT)	49
2.11.4	Fibrinogen level	49
3	Chapter Three Results	51
4	Chapter Four	61

	Discussion, conclusion and recommendations	
4	References and appendices	65
4.1	References	65
4.2	appendices	68

## Tables

NO	Name of the Table	Page
1.1	<i>coagulation factor and relative substance</i>	10
1.2	<i>coagulation factor and relative substance</i>	11
1.2	Fibrinogen Levels of Controls and Patients of Cirrhosis	38
1.3	Fibrinogen Levels in Uncomplicated and Complicated Liver Cirrhosis	39
1.4	coagulation marker in each group of patient	40
1.5	statistical tests of mean against reference constants, correlation for study group	41
3.1	Demographic characteristic of study participants	50
3.2	Demographic of diseases types	51
3.3	Compare mean of parameters of case and control	52
3.4	Mean, SD, minimum, and maximum, of coagulation parameters in test group.	53
3.5	Mean, SD, minimum, and maximum, of control group	54

3.6	Effect of age group on the study of coagulations parameters	55
3.7	Mean of PT, PTT, TT, and fibrinogen among sex group of liver	56
3.8	mean of study group according to marital status	57
3.9	Mean of coagulation parameters PT, PTT, with liver disease types	58
3.10	Mean of coagulation parameters TT, fibrinogen, with liver disease	59

## Abbreviations

ADP	Adenosine diphosphate.
AT	Anti thrombin.
BSS	Bernard Soulier Syndrome.
CT	Clotting time.
DIC coagulation.	Disseminated intravascular
DVT	Deep venous thrombosis.
EDTA	Ethylene diamine tetra acetic acid.
FDPs	Fibrin degradation product.
GP	Glycoprotein.
HMWK	High molecular weight kininogen.
PAI-1	Plasminogen activator inhibitor.
PPP	platelet poor plasma.
PDGF	Platelet derived growth factor.
TPA	Tissue plasminogen activator.
vWF	von will brand factor.